An improved diagnostic assay for Lambert-Eaton myasthenic syndrome.

M Motomura, I Johnston, B Lang, A Vincent and J Newsom-Davis

Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.

A new immunoprecipitation assay has been established for detecting antibodies to voltage-gated calcium channels (VGCCs) in Lambert-Eaton myasthenic syndrome (LEMS), using 125I-omega-conotoxin MVIIC, which binds to P-type VGCCs, to label extracts of human cerebellum. Fifty six of 66 serum samples (85%) from patients with clinically and electrophysiologically definite LEMS were positive for the presence of VGCC antibodies, defined as a titre > 3 SD above the mean for the healthy controls (n = 10). All disease controls (n = 40) were negative. This sensitive immunoassay should prove valuable in the diagnosis of LEMS.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Truffert, A., Allali, G., Vokatch, N., Lalive, P. H (2009). Mild clinical expression of Lambert-Eaton myasthenic syndrome in a patient with HIV infection. BMJ Case Reports 2009: bcr0820080649-bcr0820080649 [Abstract] [Full Text]  
• Truffert, A., Allali, G., Vokatch, N., Lalive, P. H (2007). Mild clinical expression of Lambert Eaton myasthenic syndrome in a patient with HIV infection. J. Neurol. Neurosurg. Psychiatry 78: 910-911 [Full Text]  
• de Beukelaar, J. W., Smitt, P. A. S. (2006). Managing paraneoplastic neurological disorders.. The Oncologist 11: 292-305 [Abstract] [Full Text]  
• Monstad, S.E., Drivsholm, L., Storstein, A., Aarseth, J.H., Haugen, M., Lang, B., Vincent, A., Vedeler, C.A. (2004). Hu and Voltage-Gated Calcium Channel (VGCC) Antibodies Related to the Prognosis of Small-Cell Lung Cancer. JCO 22: 795-800 [Abstract] [Full Text]  
• Abicht, A., Lochmuller, H. (2002). What's in the serum of seronegative MG and LEMS?: MuSK et al.. Neurology 59: 1672-1673 [Full Text]  
• Nakao, Y.K., Motomura, M., Fukudome, T., Fukuda, T., Shiraishi, H., Yoshimura, T., Tsujihata, M., Eguchi, K. (2002). Seronegative Lambert-Eaton myasthenic syndrome: Study of 110 Japanese patients. Neurology 59: 1773-1775 [Abstract] [Full Text]  
• Wirtz, P W, Sotodeh, M, Nijnuis, M, van Doorn, P A, van Engelen, B G M, Hintzen, R Q, de Kort, P L M, Kuks, J B, Twijnstra, A, de Visser, M, Visser, L H, Wokke, J H, Wintzen, A R, Verschuuren, J J (2002). Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry 73: 766-768 [Abstract] [Full Text]  
• Graus, F., Lang, B., Pozo-Rosich, P., Saiz, A., Casamitjana, R., Vincent, A. (2002). P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59: 764-766 [Abstract] [Full Text]  
• Oyaizu, T., Okada, Y., Sagawa, M., Yamakawa, K., Kuroda, H., Fujihara, K., Itoyama, Y., Tanita, T., Motomura, M., Kondo, T. (2001). Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma. J. Thorac. Cardiovasc. Surg. 121: 1005-1006 [Full Text]  
• Maddison, P, Lang, B, Mills, K, Newsom-Davis, J (2001). Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J. Neurol. Neurosurg. Psychiatry 70: 212-217 [Abstract] [Full Text]  
• Buchwald, B., de Baets, M., Luijckx, G.-J., Toyka, K. V. (1999). Neonatal Guillain-Barre syndrome: Blocking antibodies transmitted from mother to child. Neurology 53: 1246-1246 [Abstract] [Full Text]  
• Dalmau, J. O., Posner, J. B. (1999). Paraneoplastic Syndromes. Arch Neurol 56: 405-408 [Full Text]  
• Benatar, M.G. (1999). Calcium channelopathies. QJM 92: 133-141 [Full Text]  
• Maddison, P., Newsom-Davis, J., Mills, K. R (1998). Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry 65: 213-217 [Abstract] [Full Text]  
• Kumakura, S., Ishikura, H., Kobayashi, S. (1998). Bone Marrow Necrosis and the Lambert-Eaton Syndrome Associated with Interferon Alfa Treatment. NEJM 338: 199-200 [Full Text]